On February 2, 2022, Halozyme Therapeutics, Inc. announced that Elaine Sun is stepping down from her position as senior vice president of the company, effective immediately, to pursue another opportunity. On February 2, 2022, Nicole LaBrosse was appointed as senior vice president of the company, effective immediately. Ms. LaBrosse has served as the company's vice president, finance and accounting since January 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.29 USD | +2.17% | +1.07% | +19.83% |
22/05 | Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing | MT |
07/05 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.83% | 563.7Cr | |
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr | |
+77.64% | 887.31Cr |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Announces Executive Changes